Chinese Journal of Pharmacovigilance ›› 2015, Vol. 12 ›› Issue (9): 547-551.
Previous Articles Next Articles
SONG Yang, YOU Xiao-min, ZONG Mao-mao, YANG Yue
Received:
2015-08-12
Revised:
2015-12-07
Online:
2015-09-08
Published:
2015-12-07
CLC Number:
SONG Yang, YOU Xiao-min, ZONG Mao-mao, YANG Yue. Research of How Traditional Chinese Medicine Can Be Registered as OTC Drug in USA[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 547-551.
[1] 郭莹,王敬博,张宛莹,等.中美两国药品分类管理制度比较及启示[J].中国药事,2010,24(6)612-614. [2] 余辉,吴蓬.国外处方药与非处方药制度概况[J].中国药学杂志,1996,31(6):368-371. [3] U.S. Food and Drug Administration. Office of Drug Evaluation Ⅳ:What We Do [EB/OL]. (2014-12-30) [2015-08-02].http://www.fda.gov/About FDA/Centers Offices/Office of Medical Products and Tobacco/ CDER/ ucm106342.htm. [4] U.S. Food and Drug Administration. Nonprescription Drugs Advisory Committee [EB/OL].(2014-05-11)[2015-08-02].http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Non- prescription Drugs Advisory Committee/default.htm. [5] 王建英.美国药品申报与法规管理[M].北京:中国医药科技出版社,2005:357. [6] U.S. Food and Drug Administration Center for Drug Evaluation and Research.Guidance for industry:Time and Extent Applications for Nonprescription Drug Products[EB/OL]. (2011-09)[2015-08- 02]. http://www.fda.gov/downloads/drugs/guidancecomplianceregul-atoryinformation/guidances/ucm078902.pdf. [7] U.S. Government Publishing Office. Labeling for Bronchodilators To Treat Asthma;Cold, Cough,Allergy,Bronchodilator,and Antiasthmatic Drug Products for Over-the-Counter Human Use [EB/OL]. (2011-07-26) [2015-08-02].http://www.gpo.gov/fdsys/pkg/FR-2011-07-26/pdf/2011-18347.pdf. [8] U.S. Food and Drug Administration Center for Drug Evaluation and Research.Guidance for industry:Botanical drug products[EB/OL].(2004-06)[2015-08-02]. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm-070491.pdf. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
[3] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
[4] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
[5] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
[6] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
[7] | TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384. |
[8] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
[9] | PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263. |
[10] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
[11] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
[12] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
[13] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
[14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[15] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||